Oxford BioDynamics (GB:OBD) has released an update.
Oxford BioDynamics Plc, a biotech firm specializing in precision medicine tests using its EpiSwitch® 3D genomics platform, has granted over 10 million share options to its employees, including to its CEO, Dr Jon Burrows, as part of its 2016 Employee Share Option Plan. The options, with a 9p exercise price, will vest over three years starting from March 2025. This move aims to incentivize staff within the framework of the company’s growth and development strategy in the personalized healthcare market.
For further insights into GB:OBD stock, check out TipRanks’ Stock Analysis page.
